SF-1126
CAS No. 936487-67-1
SF-1126( SF 1126 | SF1126 )
Catalog No. M16703 CAS No. 936487-67-1
SF-1126?is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 732 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSF-1126
-
NoteResearch use only, not for human use.
-
Brief DescriptionSF-1126?is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins.
-
DescriptionSF-1126?is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins; blocks expression levels of c-Myc in HCC cells, inhibits proliferation, cell cycle, apoptosis, PI3K/AKT/mTOR and Ras/Raf/MAPK pathway; shows significant antitumor activity in vivo.Liver Cancer Phase 1 Clinical.
-
In VitroSF1126 (0-6 μM; 48 hours) inhibits Hep3B, HepG2, SK-Hep1, and Huh7 cells proliferation with IC50s of 5.05, 6.89, 3.14, and 2.14 μM, respectively.SF1126 (1-10 μM; 24 hours) results in cell-cycle arrest with a proportional increase in G0-G1 and a decrease in the number of cells in the S-phase in Hep 3B, Hep G2, SK-Hep1, and Huh7 cells.SF1126 (0.5-2.5 μM; pre-30 minutes) and sorafenib suggests that combined treatment of SF1126 and sorafenib blocks multiple key enzymes in PI3K/AKT/mTOR and Ras/Raf/MAPK pathway. Cell Viability Assay Cell Line:Hep3B, HepG2, SK-Hep1, and Huh7 cells Concentration:0 μM; 1 μM; 2 μM; 3 μM; 4 μM; 5 μM; 6 μM Incubation Time:48 hours Result:Resulted in an increased inhibition of HCC proliferation. Cell Cycle Analysis Cell Line:Hep3B, HepG2, SK-Hep1, and Huh7 cells Concentration:1 μM; 5 μM; 10 μM Incubation Time:24 hours Result:Induced cell-cycle arrest.Western Blot Analysis Cell Line:Hep3B, HepG2, SK-Hep1, and Huh7 cells Concentration:0.5 μM and 2.5 μM Incubation Time:Pre-30 mins Result:Suppressed phosphorylation of AKT, p70S6K, 4EBP1, and ERK in all the cell lines together with sorafenib.
-
In Vivo——
-
SynonymsSF 1126 | SF1126
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3K
-
Research AreaCancer
-
IndicationLiver Cancer
Chemical Information
-
CAS Number936487-67-1
-
Formula Weight852.84
-
Molecular FormulaC39H48N8O14
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C([O-])[C@H](CO)NC([C@H](CC(O)=O)NC(CNC([C@H](CCCNC(N)=N)NC(CCC(OC[N+]1(C2=CC(C3=C(O2)C(C4=CC=CC=C4)=CC=C3)=O)CCOCC1)=O)=O)=O)=O)=O
-
Chemical Name(4-oxo-4-((4-(4-oxo-8-phenyl-4H-chromen-2-yl)morpholino-4-ium)methoxy)butanoyl)-L-arginylglycyl-L-aspartyl-L-serinate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Garlich JR, et al. Cancer Res. 2008 Jan 1;68(1):206-15.
2. Dittmann A, et al. ACS Chem Biol. 2014 Feb 21;9(2):495-502.
3. Erdreich-Epstein A, et al. Oncotarget. 2016 Nov 16. doi: 10.18632/oncotarget.13386.
molnova catalog
related products
-
GDC-0326
A potent, selective, orally available PI3Kα inhibitor with Ki of 0.2 nM; displays 133, 20 and 33-fold selectivity over PI3Kβ, PI3Kδ and PI3Kγ, respectively.
-
AS2541019
AS2541019 is a novel potent, selective, orally active PI3Kδ inhibitor with IC50 of 20.1 nM.
-
PI-103
A potent, dual class I PI3K/mTOR inhibitor with IC50 of 2/3/3/15/ for p110α/β/δ/γ, respectively.
Cart
sales@molnova.com